Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN: Crizanlizumab in Sickle Cell Disease
NCT01895361Phase 2Completed
- Sponsor
- Reprixys Pharmaceutical Corporation
- Start
- Jul 2013
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of crizanlizumab in sickle cell disease (SCD), sponsored by Reprixys Pharmaceutical Corporation. Started Jul 2013; status: completed.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01895361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01895361.